115 related articles for article (PubMed ID: 10676721)
1. Effect of 1,25-dihydroxyvitamin D3 and calcium carbonate on bone loss associated with long-term renal transplantation.
Cueto-Manzano AM; Konel S; Freemont AJ; Adams JE; Mawer B; Gokal R; Hutchison AJ
Am J Kidney Dis; 2000 Feb; 35(2):227-36. PubMed ID: 10676721
[TBL] [Abstract][Full Text] [Related]
2. Bone loss in long-term renal transplantation: histopathology and densitometry analysis.
Cueto-Manzano AM; Konel S; Hutchison AJ; Crowley V; France MW; Freemont AJ; Adams JE; Mawer B; Gokal R
Kidney Int; 1999 May; 55(5):2021-9. PubMed ID: 10231467
[TBL] [Abstract][Full Text] [Related]
3. Changes in quantitative bone histomorphometry in aging healthy men.
Clarke BL; Ebeling PR; Jones JD; Wahner HW; O'Fallon WM; Riggs BL; Fitzpatrick LA
J Clin Endocrinol Metab; 1996 Jun; 81(6):2264-70. PubMed ID: 8964862
[TBL] [Abstract][Full Text] [Related]
4. The role of tacrolimus (FK506)-based immunosuppression on bone mineral density and bone turnover after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol.
Stempfle HU; Werner C; Siebert U; Assum T; Wehr U; Rambeck WA; Meiser B; Theisen K; Gärtner R
Transplantation; 2002 Feb; 73(4):547-52. PubMed ID: 11889427
[TBL] [Abstract][Full Text] [Related]
5. Alendronate prevents further bone loss in renal transplant recipients.
Giannini S; D'Angelo A; Carraro G; Nobile M; Rigotti P; Bonfante L; Marchini F; Zaninotto M; Dalle Carbonare L; Sartori L; Crepaldi G
J Bone Miner Res; 2001 Nov; 16(11):2111-7. PubMed ID: 11697808
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and treatment of decreased bone density in renal transplant recipients: a randomized prospective trial of calcitriol versus alendronate.
Jeffery JR; Leslie WD; Karpinski ME; Nickerson PW; Rush DN
Transplantation; 2003 Nov; 76(10):1498-502. PubMed ID: 14657693
[TBL] [Abstract][Full Text] [Related]
7. Effect of calcitriol on bone loss after cardiac or lung transplantation.
Sambrook P; Henderson NK; Keogh A; MacDonald P; Glanville A; Spratt P; Bergin P; Ebeling P; Eisman J
J Bone Miner Res; 2000 Sep; 15(9):1818-24. PubMed ID: 10977001
[TBL] [Abstract][Full Text] [Related]
8. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
9. Association of sex hormone status with the bone loss of renal transplant patients.
Cueto-Manzano AM; Freemont AJ; Adams JE; Mawer B; Gokal R; Hutchison AJ
Nephrol Dial Transplant; 2001 Jun; 16(6):1245-50. PubMed ID: 11390727
[TBL] [Abstract][Full Text] [Related]
10. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.
Meng Y; Zhang H; Li Y; Li Q; Zuo L
Bone; 2014 Jan; 58():168-76. PubMed ID: 24145307
[TBL] [Abstract][Full Text] [Related]
11. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
[TBL] [Abstract][Full Text] [Related]
12. Lumbar bone mineral density in renal transplant patients on neoral and tacrolimus: a four-year prospective study.
Marcén R; Caballero C; Pascual J; Teruel JL; Tenorio M; Ocaña J; Villafruela JJ; Burgos FJ; Fernández AM; Muriel A; Ortuño J
Transplantation; 2006 Mar; 81(6):826-31. PubMed ID: 16570003
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of calcitriol in treating glucocorticoidinduced osteoporosis in patients with nephrotic syndrome: an open-label, randomized controlled study.
Chen Y; Wan JX; Jiang DW; Fu BB; Cui J; Li GF; Chen CM
Clin Nephrol; 2015 Nov; 84(5):262-9. PubMed ID: 26396095
[TBL] [Abstract][Full Text] [Related]
14. The effect of oral 1 alpha-hydroxycalciferol treatment on bone mineral density in hemodialysis patients.
Morita A; Tabata T; Inoue T; Nishizawa Y; Morii H
Clin Nephrol; 1996 Dec; 46(6):389-93. PubMed ID: 8982555
[TBL] [Abstract][Full Text] [Related]
15. Ibandronate in stable renal transplant recipients with low bone mineral density on long-term follow-up.
Tillmann FP; Schmitz M; Jäger M; Krauspe R; Rump LC
Int Urol Nephrol; 2016 Feb; 48(2):279-86. PubMed ID: 26498632
[TBL] [Abstract][Full Text] [Related]
16. Prevention of osteoporosis after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol.
Stempfle HU; Werner C; Echtler S; Wehr U; Rambeck WA; Siebert U; Uberfuhr P; Angermann CE; Theisen K; Gärtner R
Transplantation; 1999 Aug; 68(4):523-30. PubMed ID: 10480411
[TBL] [Abstract][Full Text] [Related]
17. Alendronate is effective to treat bone loss in renal transplantation recipients.
Lan G; Peng L; Xie X; Peng F; Wang Y; Yu S
Transplant Proc; 2008 Dec; 40(10):3496-8. PubMed ID: 19100422
[TBL] [Abstract][Full Text] [Related]
18. Bone disease in long-term adult kidney transplant patients with normal renal function.
Montalban C; de Francisco AL; Mariñoso ML; Zubimendi JA; García Unzueta M; Amado JA; Arias M
Kidney Int Suppl; 2003 Jun; (85):S129-32. PubMed ID: 12753284
[TBL] [Abstract][Full Text] [Related]
19. Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidism.
Abdelhadi M; Nordenström J
J Clin Endocrinol Metab; 1998 Nov; 83(11):3845-51. PubMed ID: 9814456
[TBL] [Abstract][Full Text] [Related]
20. Effect of calcitriol on bone mineral density in premenopausal Chinese women taking chronic steroid therapy. A randomized, double blind, placebo controlled study.
Lambrinoudaki I; Chan DT; Lau CS; Wong RW; Yeung SS; Kung AW
J Rheumatol; 2000 Jul; 27(7):1759-65. PubMed ID: 10914864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
